<scp> <sup>166</sup> Ho‐RadioEmbolizaTiOn </scp> Using personalized <scp>prediCtive</scp> dosimetry in patients with Hepatocellular carcinoma: A prospective, single‐centre study ( <scp>RETOUCH</scp> )
Personalized <sup>166</sup>Ho-SIRT with a tumour delivered dose ≥150 Gy was feasible and safe for HCC patients with promising response rates.
Authors
- Benoît Collette (ORCID: https://orcid.org/0000-0002-2689-7579)
- Rodrigo Moreno‐Reyes (ORCID: https://orcid.org/0000-0001-8686-4907)
- Irina Vierasu (ORCID: https://orcid.org/0000-0002-0640-0916)
- Gontran Verset (ORCID: https://orcid.org/0000-0003-1912-6327)
- Ana‐Maria Bucalau (ORCID: https://orcid.org/0000-0003-0444-7806)
- Illario Tancredi (ORCID: https://orcid.org/0000-0001-5190-2635)
- Martina Pezzullo
- Fadi Tannouri
Institutions
- Université Libre de Bruxelles (BE)
- Institut Paoli-Calmettes (FR)
Publication Details
- Journal
- Liver International
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1111/liv.15923
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.37